Journal Article |
| K Lee, S Chokshi, T Joshi, M Cummings, V Ramirez-Alcantara, EA Turbat-Herrera, RP Rocconi, JM Scalici, JY Pierce, N Jones. Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage. Gynecologic Oncology 2025; 200:80-87. | 2025 |
| KS Vikramdeo, O Miree, S Anand, A Sharma, SK Srivastava, S Singh, RP Rocconi, AP Singh. MYB/AKT3 axis is a key driver of ovarian cancer growth, aggressiveness, and chemoresistance. Journal of Ovarian Research 2025; 18(1) | 2025 |
| A Yousif, J Ngo, D Abdel-Gadir, RP Rocconi, P Timmins, J Lachance, JM Straughn, S Dewdney, J Lachance, B Mize, I Chefetz. Conversion from minimally invasive surgical approaches to open surgery among patients with endometrial cancer in the SGO Clinical Outcomes registry. Annals of Surgical Oncology. 2025; (5):3458-3464. | 2025 |
| IL Romero, E Lengyel, AE Wahner Hendrickson, GC Rodriguez, CA Leath 3rd, RP Rocconi, MJ Goodheart, S Dewdney, T Karrison, GF Fleming, SD Yamada Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025; 8:194:18-24. | 2025 |
| M Sonavane, J Hedlich, VL Dal Zotto, M Tang, J Nemunaitis, L Stanbery, A Walter, E Bognar, RP Rocconi, and NR Gassman. Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer. Gynecololic Oncology. 2025; 192:65-72. | 2025 |
| A Wilhite, S Wu, J Xiu, GT Gibney, T Phung, GK In, TJ Herzog, D Khabele, BK Erickson, J Brown, RP Rocconi, JY Pierce, JM Scalici, NL Jones. A paradigm shift in our understanding of vulvovaginal melanoma as a distinct tumor type compared to cutaneous melanoma. Gynecologic Oncology 2024: 188:13-21. | 2024 |
| J Nemunaitis, L Stanbery, A Walter, G Wallraven, A Nemunaitis, S Horvath, E Bognar, D Rao, S Engle, S Brun, M Ghisoli; RP Rocconi; BJ Monk; RL Coleman. Gemogenovatucel-T (Vigil): bi-shRNA Plasmid-Based Targeted Immunotherapy. Future Oncology 2024; 2024;20(29):2149-2164. | 2024 |
| SS Winkler, C Tian, Y Casablanca, NW Bateman, S Jokajtys, CW Kucera, CM Tarney, JK Chan, MT Richardson, DS Kapp, CI Liao, CA Hamilton, CA Leath III, M Reddy, ML Cote, TD O’Connor, NL Jones, RP Rocconi, MA Powell, J Farley, CD Shriver, TP Conrads, NT Phippen, GL Maxwell, M Darcy. Racial, Ethnic and Country of Origin Disparities in the Diagnosis of Aggressive Endometrial Cancer Histologic Subtypes. Gynecologic Oncology 2024; 184:31-42. | 2024 |
| CW Kucera, NP Chappell, C Tian, MT Richardson, CM Tarney, CA Hamilton, JK Chan, DS Kapp, CA Leath III, Y Casablanca, C Rojas, CA Sitler, L Wenzel, A Klopp, NL Jones, RP Rocconi, JH Farley, TD O’Connor, CD Shriver, NW Bateman, TP Conrads, NT Phippen, GL Maxwell, KM Darcy Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors. Gynecologic Oncology 2024; 184: 224-235. | 2024 |
| C Mani, K Tripathi, S Chaudhary, RR Somasagara, RP Rocconi, C Crasto, M Reedy, M Athar, K Palle Corrigendum to Hedgehog/GLI1 transcriptionally regulates FANCD2 in ovarian tumor cells: Its inhibition induced HR-Deficiency and synergistic lethality with PARP inhibition. Neoplasia 2024; 50: 100978. | 2024 |
| J Oh, M Barve, N Senzer, P Aaron, L Manning, G Wallraven, E Bognar, L Stanbery, S Horvath, M Manley, J Nemunaitis, A Walter, RP Rocconi. Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" Gynecologic Oncology Reports 2021; 36: 100740. | 2024 |
| J Nemunaitis, L Stanbery, A Walter, RP Rocconi, P Stephens. Rationale for the use of homologous recombination proficient molecular profile as a biomarker for therapeutic targeting in ovarian cancer. Oncology Reviews 2023; Sep 20:17:11471. | 2023 |
| J Nemunaitis, L Stanbery, D Willoughby, E Bognar, S Brun, A Walter, BJ Monk, RP Rocconi, K Choucair, RL Coleman. Clonal neoantigen: Emerging “mechanism based” biomarker of immunotherapy response. Cancers 2023, 15, 5616. | 2023 |
| W Cui, RP Rocconi, R Thota, RA Anderson, SS Bruinooge, IA Comstock, N Denduluri, A Gassman, J Gralow, KJ Hutt, L Amiri-Kordestani, M Lambertini, J Leighton, KH Lu, S Mostoufi-Moab, T Pollastro, S Pradhan, H Saber, C Schenkel, D Spratt, S Wedam, KA Phillips. Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement Lancet Oncol. 2023; Oct, 24(10):e415-e423. | 2023 |
| CW Kucera, C Tian, CM Tarney, C Presti, S Jokjtys, S Winkler, Y Casablanca, NW Bateman, P Mhawech-Fauceglia, L Wenzel, CA Hamilton, JK Chan, NL Jones, RP Rocconi, TD O’Connor, J Farley, CD Shriver, TP Conrads, NT Phippen, GL Maxwell, KM Darcy Factors Associated with Survival Disparities between Non-Hispanic Black and White Patients with Uterine Cancer. JAMA Oncology Network Open. 2023; 3: 6 (4): e238437. | 2023 |
| ZA Kopelman, C Tian, J Tumas, NT Phippen, CM Tarney, ER Hope, SS Winkler, S Jokajtys, CW Kucera, JK Chan, MT Richardson, DS Kapp, CA Hamilton, CA Leath III, NL Jones, RP Rocconi, JH Farley, AA Secord, CM Cosgrove, MA Powell, A Klopp, JL Walker, GF Fleming, NW Bateman, TP Conrads, GL Maxwell, KM Darcy. Disease Progression, Survival, and Molecular Disparities in Black and White Patients with Endometrioid Endometrial Carcinoma in Real-World Registries and GOG/NRG Oncology Randomized Phase III Clinical Trials. Gynecologic Oncology. 2024 Apr;183:103-114. | 2023 |
| RP Rocconi, BJ Monk, A Walter, TJ Herzog, E Galanis, L Manning, E Bognar, G Wallraven, L Stanbery, P Aaron, N Senzer, RL Coleman, J Nemunaitis. Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.” Gynecologic Oncology 2022; S0090-8258 (22) 01924-2. | 2023 |
| WN Goldsberry, BS Norquist, RP Rocconi, S Modesitt, RR Urban. Navigating Maintenance Therapy for Homologous Recombinant Proficient Patients. Gynecologic Oncology Reports 2022; 44: 101103. | 2022 |
| RP Rocconi, L Stanbery, M Tang, A Walter, BJ Monk, TJ Herzog, R Coleman, L Manning, G Wallraven, S Horvath, E Bognar, N Senzer, S Brun, J Nemunaitis. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Nature Communications Med 2022; 29; 2: 106. | 2022 |
| CP Williams, GB Rocque, A Azuero, KM Kenzik, GR Williams, RP Rocconi, P Sharma, W Demark-Wahnefried, M Martin, M Pisu Impact of lay navigation on utilization and Medicare spending for cancer survivors in the “Deep South”. Journal of Cancer Survivorship 2022; 16 (4): 705-713. | 2022 |
| A Wilhite, Y Baca, J Xiu, R Paladugu, A ElNaggar, J Brown, IS Winer, R Morris, BK Erickson, AB Olawaiye, M Powell, WM Korn, RP Rocconi, D Khabele, NL Jones. Molecular profiles of endometrial cancer tumors among Black patients. Gynecologic Oncology 2022; 166(1): 108-116. | 2022 |
| RP Rocconi, EE Stevens, JN Bottsford-Miller, SA Ghamande, J Elder, LL DeMars, A Munkarah, P Aaron, L Stanbery, G Wallraven, E Bognar, M Manley, S Horvath, L Manning, A Walter, E Galanis, T Herzog, BJ Monk, RL Coleman, J Nemunaitis Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Therapy 2022; 29 (3-4): 369-382 | 2022 |
| RP Rocconi, A Wilhite, L Pannell, D Billheimer, L Schambeau, MA Finan. A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen. Gynecologic Oncology 2022; 164(1): 181-186. | 2022 |
| A Walter, RP Rocconi, BJ Monk, TJ Herzog, L Manning, E Bognar, G Wallraven, P Aaron, S Horvath, M Tang, L Stanbery, RL Coleman, J Nemunaitis A Walter, RP Rocconi, BJ Monk, TJ Herzog, L Manning, E Bognar, G Wallraven, P Aaron, S Horvath, M Tang, L Stanbery, RL Coleman, J Nemunaitis. Gemogenovatucel-T (Vigil) immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology 2021; 163(3): 459-464. | 2021 |
| K Grette, A White, E Awad, JM Scalici, JY Pierce, RP Rocconi, N Jones. Not immune to inequity: two decades of minority under-representation in immunotherapy trials for breast and gynecologic cancers. International Journal of Gynecologic Cancers 2021; 31(11): 1403-1407. | 2021 |
| C Mani, K Tripathi, SC Chaudhary, R Somasagara, RP Rocconi, C Crasto, M Reedy, M Athar, K Palle Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition. Neoplasia 2021; 23 (9): 1002-1015. | 2021 |
| DM O’Malley, LM Randall, CC Gunderson, RL Coleman, JL Hays, KN Moore, W Naumann, RP Rocconi, BM Slomovitz, KS Tewari, M Ancukiewicz, WO Feliu, BJ Monk. A randomized Phase II study of balstilimab alone or in combination with zalifrelimab in second-line cervical cancer. Future Oncology 2021; 17 (26):3433-3443. | 2021 |
| MA Khan, KS Vikramdeo, SK Sudan, S Singh, S Dasgupta, A Wilhite, RP Rocconi, AP Singh Platinum-resistant ovarian cancer: from drug resistance mechanisms to liquid biopsy- based biomarkers for disease management. Seminars in Cancer Biology 2021; 77: 99-109. | 2021 |
| RP Rocconi, L Stanbery, LM da Silva, RA Barrington, P Aaron, L Manning, S Horvath, G Wallraven, E Bognar, A Walter, J Nemunaitis Long term follow-up Gemogenovatucel-T (Vigil) Survival and Molecular Signals of immune response in recurrent ovarian cancer. Vaccines 2021; 9 (8): 894. | 2021 |
| O Miree, SK Srivastava, MA Khan, F Sameeta, S Acharya, H Ndetan, KP Singh, KL Hertweck, S Dasgupta, L Madeira da Silva, RP Rocconi, JE Carter, S Singh, AP Singh Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer Scientific Reports 2021; 11(1): 12901. | 2021 |
| RP Rocconi, BJ Monk, A Walter, TJ Herzog, E Galanis, L Manning, E Bognar, G Wallraven, L Stanbery, P Aaron, N Senzer, RL Coleman, J Nemunaitis. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology 2021; 161(3): 676-680. | 2021 |
| J Oh, M Barve, N Senzer, P Aaron, L Manning, G Wallraven, E Bognar, L Stanbery, S Horvath, M Manley, J Nemunaitis, RP Rocconi Long-term follow-up of phase 2A trial results involving advanced ovarian cancer patients treated with Vigil in frontline maintenance. Gynecologic Oncology Reports 2021; 36: 100740. | 2021 |
| O Miree, SK Srivastava, S Dasgupta, S Singh, RP Rocconi, AP Singh Current and futuristic roadmap of ovarian cancer management: An overview. Adv Exp Med Biol. 2021; 1330: 1-19. | 2021 |
| RP Rocconi, EA Grosen, SA Ghamande, J Chan, MA Barve, J Oh, D Tewari, PC Morris, EE Stevens, JN Bottsford-Miller, M Tang, P Aaron, S Horvath, G Wallraven, E Bognar, L Manning, J Nemunaitis, D Shanahan, BM Slomovitz, TJ Herzog, BJ Monk, RL Coleman BRCA1/2-Wild type Frontline Stage III/IV Ovarian Cancer Relapse Free and Overall Survival Advantage: Randomized Double-Blind Placebo Controlled Trial of Vigil Immunotherapy (VITAL study). Lancet Oncology 2020; 21(12): 1661-1672. | 2020 |
| J Oh, M Barve, N Senzer, P Aaron, L Manning, G Wallraven, E Bognar, L Stanbery, S Horvath, M Manley, J Nemunaitis, RP Rocconi Long-term follow-up of phase 2A trial results involving advanced ovarian cancer patients treated with Vigil in frontline maintenance. Gynecol Oncol Rep. 2020 Sep 17;34:100648. | 2020 |
| GK Patel, J Perry, O Abdul-Rahim, AE Frankel, D Cameron, W Taylor, RP Rocconi, C Nelson, AP Singh, M Khushman EGFR activating mutation (E746 T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by EGFR A647T-mediated resistance: A case report and literature review. Journal of Cancer Research and Therapeutics 2020; 16(4): 950-954 | 2020 |
| S Morand, L Stanbery, A Walter, RP Rocconi, J Nemunaitis. BRCA1/2 mutation status impact on autophagy and immune response: Unheralded target. J Natl Cancer Inst Clinical Spectrum 2020; 4(6):pkaa077. | 2020 |
| C Rojas, C Tian, MA Powell, JK Chan, NW Bateman, TP Conrads, RP Rocconi, NL Jones, CD Shriver, CA Hamilton, GL Maxwell, Y Casablanca, and KM Darcy Racial Disparities in Uterine and Ovarian Carcinosarcoma: A Population-Based Analysis of Treatment and Survival. Gynecologic Oncology; 2020; 157(1): 67-77. | 2020 |
| NL Jones, J Xiu, RP Rocconi, TJ Herzog, IS Winer Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. Gynecologic Oncology; 2020; 156(2): 393-399. | 2020 |
| MA Khan, GK Patel, SK Srivastava, JE Carter, JY Pierce, RP Rocconi, S Singh, AP Singh Looking at cancer health disparities without the colored lenses. Cancer Health Disparities Journal; 2019; 3: e1-e9. | 2019 |
| K Grette, B Long, MA Finan, RP Rocconi Intraperitoneal (IP) port cytology after completion of primary therapy of advanced stage ovarian cancer: A novel approach to a “second look”. Gynecologic Oncology 2019; 154(2):290-293. | 2019 |
| GB Rocque, CP Williams, HD Miller, SB Wheeler, M Pisu, O Hull, RP Rocconi, KM Kenzik. Impact of travel time on hospitalization rates and cost by phase of care for older cancer patients in the era of value-based healthcare. Journal of Clinical Oncology 2019: Aug 1;37(22):1935-1945. | 2019 |
| I Vergote, G Scambia, DM O’Malley, B Van Calster, SY Park, JM Del Campo, W Meier, A Bamias, N Colombo, RM Wenham, A Covens, C Marth, M Mirza, JR Kroep, H Ma, CA Pickett, BJ Monk. (RP Rocconi-collaborator) Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomized, double-blind, phase 3 trial. Lancet Oncology 2019; 20(6): 862-876. | 2019 |
| M Pisu, G Rocque, Jackson, K Kenzik, Taylor, Li, Sharma, Williams C, Kvale, Acemgil, MY Martin, Meneses, Demark, M Fouad, G Cantuaria, RP Rocconi, M Sullivan, EE Partridge Lay navigation across the cancer continuum for the older cancer survivors: equally beneficial for Black and White survivors? Journal of Geriatric Oncology 2019; 10 (5): 779-786. doi: 10.1016/j.jgo.2018.2018.10-013 | 2018 |
